| Adverse events; n (%) | Glaritus® (N = 86) | Lantus® (N = 85) |
| Total number of AEs | 10 (11.6) | 14 (16.4) |
| Number of subjects with at least one AE | 9 (10.5) | 12 (14.1) |
| General disorders | 2 (2.3) | 5 (5.9) |
| Urinary tract infections | 3 (3.5) | 1 (1.2) |
| Headache | 3 (3.5) | 2 (2.4) |
| Nasopharyngitis | 1 (1.2) | 3 (3.5) |
| Skin and subcutaneous tissue disorders | 0 (0.0) | 2 (2.4) |
| Decreased appetite | 1 (1.2) | 0 (0.0) |